Indometacine Aurobindo is a nonsteroidal anti-inflammatory drug (NSAID) primarily used to manage symptoms related to inflammatory or irritative states. It is commonly utilized for conditions presenting with acute episodes and chronic inflammatory joint diseases.

---

Core Therapeutic Scope

This medication is generally considered relevant for conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, and short-term soft-tissue inflammation like bursitis and tendinitis. It is also applied in managing select, unique headache disorders. It is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during symptomatic phases.

Quick Fact: Supports easing symptom burden from joint discomfort and systemic imbalance

Its core benefit lies in its ability to address multiple symptoms that interfere with daily functioning. It supports the easing of chronic symptoms, notably by assisting in easing joint stiffness and persistent pain, and provides supportive relief from systemic imbalance symptoms like fever and generalized aches. The medication may be part of symptomatic management for conditions requiring anti-inflammatory intervention.

Regulatory References

1. FDA-approved labeling on DailyMed (NIH)

Official Eligibility Profile for Indometacine Aurobindo

The use of Indometacine Aurobindo is defined by specific regulatory criteria regarding population eligibility and exclusion. These rules identify groups for whom the medicine is strictly prohibited or requires conditional use.

• Absolute Contraindications: The medicine is strictly prohibited for patients who have known hypersensitivity to Indometacin or other NSAIDs, particularly those with a history of aspirin-induced asthma or allergic reactions. Use is also contraindicated in patients with active gastrointestinal ulceration, bleeding, or perforation, and following coronary artery bypass graft (CABG) surgery.

• Age-Group Rules: The medication is not established for use in children under two years of age. Use in pediatric patients aged two and older is restricted and requires close medical monitoring. Older adults should use the medication with greater care due to an increased risk of adverse reactions.

• Physiological Status Restrictions: Indometacin is contraindicated during the third trimester of pregnancy. Use is restricted during the first two trimesters and while breastfeeding. The medicine is also not recommended for women who are attempting to conceive, based on evidence of reversible effects on fertility.

• Conditional Use: Eligibility requires caution and restricted use for individuals with advanced renal disease, severe heart failure, hepatic impairment, or pre-existing psychiatric disorders, epilepsy, or Parkinsonism.

The official regulatory profile for Indometacine Aurobindo documents several interactions that may alter the drug's exposure or potentiate effects of co-administered medicines.

Contraindicated and Restricted Combinations

Classification	Interacting Substance	Regulatory Constraint
Contraindicated	Diflunisal	Co-administration is prohibited due to a documented increase in Indometacin plasma concentration and reduced renal clearance.
Not Recommended	Other NSAIDs, Analgesic Aspirin	Concomitant use should be avoided due to the documented significant increase in the risk of gastrointestinal adverse events.

Pharmacokinetic and Pharmacodynamic Outcomes

The drug interacts with several medicine classes by affecting clearance or increasing pharmacodynamic risk.

• Exposure Alterations: Indometacin can cause a clinically relevant elevation of plasma Lithium levels and a reduction in its renal clearance. The drug also decreases the tubular secretion of Methotrexate, leading to potentiation of its toxicity. Co-administration with Digoxin can increase its serum concentration.
• Antihypertensive Antagonism: Indometacin may diminish the antihypertensive effects of medicines like ACE Inhibitors, ARBs, and Beta-Blockers. It can also reduce the natriuretic effect of Diuretics, and increase the risk of hyperkalaemia with potassium-sparing diuretics.
• Hemorrhage Risk: When combined with Anticoagulants (e.g., Warfarin) or Oral Corticosteroids, the interaction creates an additive risk of bleeding and gastrointestinal ulceration.
• Substance Interaction: Use with Alcohol is documented to intensify substance-related adverse effects, particularly the risk of gastrointestinal blood loss.

Specific cautions regarding renal deterioration are noted for co-administration with ACE Inhibitors/ARBs in elderly and volume-depleted patients.

Targeted Enzyme Inhibition and Mediator Suppression

The action of the single active ingredient is defined by its non-selective intervention across three major physiological systems via a unified molecular mechanism. The core mechanism involves non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes, which are essential for producing chemical mediators called prostaglandins. The drug suppresses the initial molecular step within the arachidonic acid cascade, restricting the formation of these signaling molecules. This modulation results in physiological changes that influence inflammation, pain signaling, and thermoregulation.

Modulation of Central and Peripheral Signaling

The mechanism operates through dual action by suppressing prostaglandin synthesis in both peripheral tissues and the Central Nervous System (CNS). Peripherally, it dampens the sensitization of pain-sensing nerves (nociceptors), and centrally, it modifies the activity of the hypothalamic center responsible for regulating core body temperature. These complementary actions alter the dynamics within nociception and thermoregulation pathways.

Physiological Control of Vascular and Cellular Response

By reducing prostaglandin levels, the drug limits the extent of vasodilation and associated vascular permeability at tissue sites. This effect on blood vessel dynamics modulates processes driven by distinct signaling patterns, restricting the vasodilation and vascular permeability, thereby influencing local fluid accumulation.

Official Guidelines for Indometacine Administration

The usage of Indometacine is governed by the principle of administering the lowest effective dosage for the shortest duration necessary. The product is available for administration via the oral route (capsules, oral suspension), rectal route (suppositories), and as an intravenous injection for specific neonatal use.

Dosage Patterns and Frequency

For chronic conditions such as rheumatoid arthritis, the starting dose is typically 25 mg taken two or three times a day. The daily dose may be adjusted in increments of 25 mg or 50 mg at weekly intervals, generally not exceeding 200 mg daily for immediate-release forms. A substantial portion of the total daily dose, up to 100 mg, may be administered at bedtime via the oral or rectal route to provide specific relief from nocturnal symptoms. For acute conditions like gouty arthritis, a higher initial dose of 50 mg is often administered three times a day, with the dose intended to be rapidly reduced and discontinued once symptoms are controlled. Acute painful shoulder (bursitis/tendinitis) is managed using 75 mg to 150 mg daily in divided doses, with a usual course of therapy lasting 7 to 14 days.

Contextual Intake and Adjustments

Oral administration must occur with food, immediately after meals, or with antacids to support tolerability. Capsules, particularly extended-release forms, must be swallowed whole and must not be crushed, opened, or chewed. Patients with significantly impaired renal function require close monitoring and may need a lower daily dosage to prevent systemic accumulation, a principle also applied when using the drug with older adults due to increased potential for adverse effects.

Administration Constraint	Labeled Instruction
Oral Timing	Must be taken with food or immediately after meals.
Form Handling	Swallow capsules whole; do not crush or chew.
Renal Adjustment	Lower daily dosage may be required.

Indometacine Aurobindo: Recent Clinical Evidence

Chronic Inflammatory Joint Diseases (RA, AS, OA)

Randomized Controlled Trials (RCTs) and comparative studies were conducted in adults diagnosed with chronic conditions like rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Research primarily examined outcomes related to physical discomfort, daily functioning, and joint stiffness. Findings describe patterns observed in the studies related to measurements on patient-reported pain scores and functional mobility scales, contributing to understanding symptom patterns.

Long-term studies were designed to monitor symptom patterns, but not to determine if the study alters the underlying progressive course of these chronic diseases. There is limited information for long-term changes observed and functional stability beyond initial trial periods.

---

Acute Pain and Inflammation (Gout, Bursitis/Tendinitis)

Studies focused on acute or disruptive episodes, such as acute gouty arthritis and localized inflammation. Research examined short-term symptom changes using pivotal trials, tracking outcomes related to physical discomfort and the time observed for changes in inflammation and swelling. Follow-up durations were limited to the acute phase. Studies observing the long-term status of future flare-ups are limited, and comparative evidence against the full range of alternative acute pain interventions is lacking.

---

Specific Prevention Scenarios (PEP, HO)

Comprehensive Systematic Reviews and Meta-analyses evaluated its role in specific prophylactic uses. Research examined outcomes related to the incidence rate of complications like Post-ERCP Pancreatitis (PEP), and the formation of Heterotopic Ossification (HO) after surgery. Studies exploring HO reported that findings were mixed regarding consistency across individual trials, and evidence quality varies across studies due to documented heterogeneity, meaning certainty remains low in some areas.

---

Research in Specific Patient Groups

The body of research primarily includes adult populations. Subgroup findings are uncertain regarding the full range of comorbid conditions. Available data on the populations studied were not as extensive for children, older adults, or pregnant groups as the evidence base for the primary adult populations. The results apply only to the populations studied and provide group patterns, not personal outcomes.

Key Studies & References

1. INDOMETHACIN capsule - Full Prescribing Information and Medication Guide (FDA Label)

Common questions about Indometacine Aurobindo (FAQ)

Q: Are there different strengths of Indometacine Aurobindo available?

A: Yes, official labeling indicates that Indometacin is provided in various strengths to suit different therapeutic needs. Regulatory documents list capsules in strengths such as 25 mg and 50 mg as being available. This range of strengths supports dosage adjustments based on official guidelines.

Q: How quickly does Indometacine Aurobindo usually start to work?

A: Studies and official information indicate that the time to start feeling relief can vary depending on the condition being addressed. For chronic issues, it may take up to a week before a change in symptoms is observed, and the full observed patterns of symptom change may take several weeks in studies of chronic conditions. For acute conditions, symptom relief may be noticed more quickly.

Q: Can taking Indometacine Aurobindo affect my blood pressure?

A: Official labeling states that this medication is associated with a risk of developing new-onset high blood pressure (hypertension) or worsening high blood pressure that a patient already has. Regulatory guidance specifies that monitoring for blood pressure changes is generally recommended during the course of treatment.

Q: Can Indometacine Aurobindo cause drowsiness or affect my ability to drive?

A: Regulatory documents indicate that the medicine may cause central nervous system (CNS) effects, which can include dizziness, lightheadedness, and drowsiness. Official safety information notes that caution regarding driving or operating machinery is necessary until the patient's individual response to the medication is known.

Q: Is it common to experience dizziness or confusion while on this drug?

A: According to the official product information, dizziness is one of the most commonly reported adverse reactions associated with this medication. Mental confusion is also listed as a potential side effect but is generally reported as being uncommon in the overall patient population. Safety notes mention that older adults may be at greater risk for these central nervous system effects.

Q: Is Indometacine Aurobindo the same product regardless of where it is manufactured?

A: Pharmaceutical regulations require that products with the same authorized name meet consistent standards of quality, potency, and active ingredient composition. However, the final patient information leaflets or the inactive ingredients (excipients) in the product formulation may vary across different regulatory territories and manufacturing sites.

Q: What kind of monitoring is recommended for people using Indometacine Aurobindo long-term?

A: Official warnings describe that long-term use of the medication necessitates periodic monitoring, which may include laboratory checks of blood pressure, kidney and liver function, and tests for signs of potential gastrointestinal bleeding or anemia.

Q: Why might a healthcare provider choose Indometacine Aurobindo over another pain reliever?

A: It is classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) with three primary actions: anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing). Official regulatory profiles indicate its mechanism of action addresses three distinct effects, which is described as appropriate for conditions such as severe inflammatory conditions, like acute gouty arthritis.

Q: Can Indometacine Aurobindo cause a severe allergic reaction?

A: Yes, official regulatory labeling reports that severe, potentially fatal, allergic reactions (anaphylactic reactions) have been associated with this medication. For this reason, the drug is listed as strictly contraindicated for individuals who have a known hypersensitivity or history of allergic reactions to the drug or other similar NSAIDs.

Q: Does Indometacine Aurobindo have a pregnancy safety category classification?

A: The U.S. FDA no longer uses letter-based pregnancy categories, but the official risk summary warns that use at or after 20 weeks of gestation is associated with risk to the fetus, particularly premature closure of the ductus arteriosus. The medication was previously classified as Category C in the former Australian TGA system.

Q: What is the typical duration of effect for a dose of Indometacine Aurobindo?

A: Regulatory information on the drug’s pharmacokinetics—how the body processes the medicine—indicates a mean terminal elimination half-life estimated to be about 4.5 hours in adults. The half-life describes the time required for the concentration of the drug in the body to decrease by half.

Q: Is Indometacine Aurobindo a controlled substance?

A: No, Indometacin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Indole-3-acetic acid derivative. Regulatory authorities, such as the US DEA, do not designate it as a controlled substance, as it is not an opioid or narcotic.

Q: Does Indometacine Aurobindo have a known risk of dependence?

A: Official regulatory information on the drug’s safety profile explicitly states that Indometacin is not associated with a known risk of physical or psychological dependence or addiction. This is consistent with its classification as an NSAID.

Q: How long after stopping Indometacine Aurobindo does it stay in the system?

A: Pharmacokinetic data from regulatory documents show that the mean half-life for elimination of the drug from the body is approximately 4.5 hours. This half-life is the main factor determining how quickly the body clears the substance.

Q: Why is Indometacine Aurobindo not considered an opioid?

A: The medication is an Indole-3-acetic acid derivative, which is classified as an NSAID. It works by inhibiting the Cyclooxygenase enzyme system to reduce pain and inflammation. This mechanism of action is entirely distinct from that of opioid analgesics, which act on different receptors in the brain and spinal cord.

Q: Can Indometacine Aurobindo affect laboratory test results?

A: Yes, regulatory documents mention that the drug may affect the results of certain laboratory tests. For instance, Indometacin can cause fluid retention and elevated potassium levels, which might impact the results of blood tests designed to measure electrolyte levels.

Q: What official information is provided about the appearance of the Indometacine Aurobindo tablet or capsule?

A: Official labeling, often found in sections describing how the product is supplied, includes details about the drug’s physical appearance. This typically covers the color, shape, and specific identifying markings (imprints) found on the capsules or tablets.

How to Store and Dispose of Indometacine Aurobindo?

The storage and disposal of Indometacine Aurobindo capsules must align with official regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Requirement	Specifics
Temperature	Store at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF). Do not freeze.
Protection	The product must be protected from excessive heat and moisture, and kept in a dry place.
Packaging	Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety	Store the medicine out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired capsules must follow local requirements and should not be thrown into household waste or flushed down the toilet (wastewater). Patients must consult a pharmacist or healthcare professional for guidance on discarding unwanted medicine.